Graft-versus-Host Disease (GVHD): A Comprehensive Guide

Overview

Graft-versus-Host Disease (GVHD) is a serious and potentially life-threatening complication that can occur after an allogeneic stem cell transplant or bone marrow transplant. In GVHD, the transplanted donor cells (the graft) recognize the recipient's body (the host) as foreign and attack it, leading to inflammation and damage in various organs.

Who Does GVHD Affect?

GVHD primarily affects individuals who have undergone:

• Allogeneic stem cell transplants (using donor cells)
• Bone marrow transplants from a donor
• Cord blood transplants from a donor

It does not occur in autologous transplants (using the patient's own cells).

Prevalence

According to the National Institutes of Health (NIH):

• Acute GVHD occurs in 30–70% of allogeneic transplant recipients.
• Chronic GVHD develops in 30–50% of patients who survive beyond the first 100 days post-transplant.
• Severe GVHD is a leading cause of non-relapse mortality after transplantation.

Symptoms

GVHD can be classified into acute (occurring within the first 100 days post-transplant) and chronic (developing after 100 days). Symptoms vary depending on the type and severity.

Acute GVHD Symptoms

Acute GVHD primarily affects the skin, liver, and gastrointestinal (GI) tract.

• Skin:
  • Rash (often starting on the palms, soles, or ears)
  • Redness (erythema)
  • Itching or burning sensation
  • Blistering or peeling in severe cases
• Gastrointestinal Tract:
  • Nausea and vomiting
  • Severe diarrhea (sometimes bloody)
  • Abdominal pain or cramping
  • Loss of appetite
• Liver:
  • Jaundice (yellowing of the skin and eyes)
  • Dark urine
  • Elevated liver enzymes (detected via blood tests)

Chronic GVHD Symptoms

Chronic GVHD can affect multiple organs and may resemble autoimmune diseases like lupus or scleroderma. Symptoms include:

• Skin:
  • Dryness or thickening
  • Tightness or sclerosis (hardening)
  • Discoloration (hyper- or hypopigmentation)
  • Hair loss or nail changes
• Mouth:
  • Dry mouth (xerostomia)
  • Mouth sores or ulcers
  • Sensitivity to spicy or acidic foods
• Eyes:
  • Dry, gritty, or burning sensation
  • Redness or inflammation
  • Light sensitivity
• Lungs:
  • Shortness of breath
  • Chronic cough
  • Bronchiolitis obliterans (a serious lung condition)
• Joints and Muscles:
  • Stiffness or pain
  • Limited range of motion
• Genital Area:
  • Vaginal dryness or ulcers (in women)
  • Painful intercourse

Causes and Risk Factors

What Causes GVHD?

GVHD occurs when the donor's immune cells (T-cells) recognize the recipient's tissues as foreign and mount an immune response against them. This is more likely when there is a mismatch between the donor and recipient's human leukocyte antigens (HLAs), which are proteins that help the immune system distinguish between the body's own cells and foreign invaders.

Risk Factors

Several factors increase the risk of developing GVHD:

• HLA mismatch between donor and recipient
• Older age of the donor or recipient
• Unrelated or mismatched donor (higher risk than matched sibling donors)
• Peripheral blood stem cell transplant (higher risk than bone marrow transplants)
• History of acute GVHD (increases risk of chronic GVHD)
• Female donor to male recipient (especially if the donor has been pregnant before)
• Intensity of the conditioning regimen (higher doses of chemotherapy or radiation before transplant)

Diagnosis

Diagnosing GVHD involves a combination of clinical evaluation, laboratory tests, and sometimes biopsies. Early diagnosis is crucial for effective management.

Diagnostic Methods

• Medical History and Physical Exam: Your doctor will review your transplant history and symptoms, and perform a physical examination to check for signs of GVHD (e.g., skin rash, mouth ulcers).
• Blood Tests:
  • Complete blood count (CBC)
  • Liver function tests (to check for elevated bilirubin or liver enzymes)
  • Kidney function tests
• Biopsy: A small tissue sample may be taken from the affected organ (e.g., skin, liver, or intestines) to confirm GVHD under a microscope.
• Imaging Tests: In cases of suspected lung or gastrointestinal GVHD, imaging tests like CT scans or endoscopies may be used.
• Scoring Systems: Doctors often use scoring systems like the Glucksberg criteria (for acute GVHD) or the NIH consensus criteria (for chronic GVHD) to assess severity.

Treatment Options

Treatment for GVHD aims to suppress the immune response while preserving the graft's ability to fight infections and cancer. The approach depends on the type (acute or chronic) and severity of GVHD.

Medications

• Corticosteroids:
  • Prednisone or methylprednisolone are first-line treatments for both acute and chronic GVHD.
  • These medications reduce inflammation and suppress the immune system.
• Calcineurin Inhibitors:
  • Cyclosporine or tacrolimus are often used in combination with steroids to prevent or treat GVHD.
• Other Immunosuppressants:
  • Mycophenolate mofetil (MMF)
  • Sirolimus
  • Methotrexate
• Biologic Therapies:
  • Ruxolitinib (Jakafi): A JAK inhibitor approved for steroid-refractory acute and chronic GVHD.
  • Ibrutinib (Imbruvica): Approved for chronic GVHD.
  • Extracorporeal photopheresis (ECP): A procedure where blood is treated with UV light to reduce immune activity.
• Topical Treatments:
  • For skin GVHD: Topical steroids, calcineurin inhibitors (e.g., tacrolimus ointment), or emollients.
  • For mouth GVHD: Steroid mouth rinses or topical anesthetics.

Supportive Care

• Infections: Prophylactic antibiotics, antivirals, and antifungals to prevent infections due to immunosuppression.
• Pain Management: Medications to manage pain from mouth sores, skin lesions, or joint stiffness.
• Nutritional Support: IV nutrition or dietary adjustments if gastrointestinal GVHD affects eating.
• Physical Therapy: To maintain mobility and strength, especially in chronic GVHD.

Emerging Treatments

Research is ongoing for new GVHD treatments, including:

• Mesenchymal stem cells (MSCs)
• Checkpoint inhibitors (e.g., ipilimumab)
• Novel JAK inhibitors

Living with Graft-versus-Host Disease (GVHD)

Managing GVHD requires a multidisciplinary approach involving your transplant team, dermatologists, gastroenterologists, and other specialists. Here are some tips for daily management:

Skin Care

• Use fragrance-free, hypoallergenic moisturizers to keep skin hydrated.
• Avoid hot showers and harsh soaps.
• Wear loose, soft clothing to reduce irritation.
• Apply sunscreen (SPF 30 or higher) to protect sensitive skin.

Oral Care

• Use a soft-bristled toothbrush and alcohol-free mouthwash.
• Rinse with salt water or prescribed steroid rinses for mouth sores.
• Avoid spicy, acidic, or crunchy foods if they cause discomfort.
• Stay hydrated and use artificial saliva for dry mouth.

Eye Care

• Use preservative-free artificial tears for dry eyes.
• Wear sunglasses to protect against light sensitivity.
• Avoid smoky or dry environments.

Diet and Nutrition

• Eat small, frequent meals if you have gastrointestinal symptoms.
• Avoid foods that trigger diarrhea or nausea.
• Work with a dietitian to ensure adequate nutrition.

Emotional and Mental Health

• Seek support from counselors, support groups, or mental health professionals.
• Stay connected with friends and family.
• Practice relaxation techniques like meditation or gentle yoga.

Prevention

While GVHD cannot always be prevented, certain strategies can reduce the risk:

• HLA Matching: Choosing a donor with the closest HLA match possible.
• T-Cell Depletion: Removing T-cells from the donor graft can reduce GVHD risk but may increase the risk of infection or relapse.
• Prophylactic Medications: Post-transplant medications like calcineurin inhibitors and methotrexate are often given to prevent GVHD.
• Alternative Donor Sources: Using cord blood or haploidentical donors (half-matched family members) with specialized protocols.

Complications

If left untreated, GVHD can lead to serious, life-threatening complications:

• Infections: Due to weakened immune system from GVHD and its treatments.
• Organ Damage:
  • Liver failure (from chronic hepatitis)
  • Lung fibrosis (bronchiolitis obliterans)
  • Kidney damage
• Malnutrition: From severe gastrointestinal GVHD.
• Secondary Cancers: Increased risk due to chronic immune suppression.
• Reduced Quality of Life: Chronic pain, fatigue, and disability.

When to Seek Emergency Care

Additional Resources

For more information, visit these reputable sources:

• Mayo Clinic
• National Cancer Institute (NCI)
• National Institutes of Health (NIH)
• Centers for Disease Control and Prevention (CDC)
• World Health Organization (WHO)
• Cleveland Clinic